New investigational drug for relapsed or refractory B-cell Non-Hodgkin Lymphoma.

Trial ID:
IRB-24-8457
Marin Xavier, MD

Inclusion Criteria

Patients must:

  • 18 years or older.
    Have a diagnosis of relapsed or refractory B-NHL who have failed or been intolerant to any approved therapy and have received at least two systemic treatment regimens.
    Have adequate organ function
    Have availability of tissue tumor block from pathology from a prior or recent biopsy.
    Agree to use a highly effective method of contraception (only for women of childbearing potential)

Exclusion Criteria

Patients must not:

  • Have had previous therapy with loncastuximab tesirine.
    Have had previous treatment with polatuzumab vedotin, glofitamab, or mosunetuzumab
    Have had an allogenic or autologous stem cell transplant within 60 days prior to starting the study drug.
    Have a history of Stevens-Johnson syndrome, toxic epidermal necrolysis, or macrophage activation syndrome (MAS)/hemophagocytic lymphohistiocytosis (HLH).
    Be breastfeeding or pregnant.
    Have had prior treatment with CAR-T.
    Have an active (or history of) autoimmune disease or immune deficiency.

Additional Info

All treatments and physician visits during the study will take place at Scripps Clinic Torrey Pines (Geisel Pavilion) and Prebys Cancer Center (Hillcrest)

For more information search NCT04970901 at www.clinicaltrials.gov

Contact Info:

  • Clinical Research Services
  • crsleadership@scrippshealth.org